drugset / Trial / NCT06737042
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
Timeline
- Start
- 2025-02-24
- Primary completion
- 2026-02-27
- Completion
- 2026-02-27
Outcome
Met primary endpoint
release “bofanglutide Injection in adults with overweight/obesity in the United States also met its primary endpoint” ganlee.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bofanglutide | Protein / enzyme biologic | 24 mg | — |
| Subject | Bofanglutide | Protein / enzyme biologic | 36 mg | — |
| Subject | Bofanglutide | Protein / enzyme biologic | 48 mg | — |
| Comparator | Tirzepatide | Peptide | 15 mg | — |